Patent: 7,446,175
✉ Email this page to a colleague
Summary for Patent: 7,446,175
| Title: | Antibodies to human IL-1β |
| Abstract: | An IL-1beta binding molecule, in particular an antibody to human IL-1beta, especially a human antibody to human IL-1beta is provided, wherein the CDRs of the heavy and light chains having amino acid sequences as defined, for use in the treatment of an IL-1 mediated disease or disorder, e.g. osteoarthritis, osteoporosis and other inflammatory arthritides. |
| Inventor(s): | Hermann Gram, Franco E. Di Padova |
| Assignee: | Novartis AG |
| Application Number: | US10/362,082 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,446,175
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | ILARIS | canakinumab | For Injection | 125319 | 17-Jun-09 | ⤷ Start Trial | 2021-08-20 |
| Novartis Pharmaceuticals Corporation | ILARIS | canakinumab | Injection | 125319 | 22-Dec-16 | ⤷ Start Trial | 2021-08-20 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
